NO327973B1 - Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder - Google Patents
Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder Download PDFInfo
- Publication number
- NO327973B1 NO327973B1 NO20021949A NO20021949A NO327973B1 NO 327973 B1 NO327973 B1 NO 327973B1 NO 20021949 A NO20021949 A NO 20021949A NO 20021949 A NO20021949 A NO 20021949A NO 327973 B1 NO327973 B1 NO 327973B1
- Authority
- NO
- Norway
- Prior art keywords
- use according
- women
- estrogen
- estradiol
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 19
- 239000003814 drug Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 title claims description 7
- 208000001132 Osteoporosis Diseases 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title claims description 6
- 230000001076 estrogenic effect Effects 0.000 title claims description 6
- 230000002265 prevention Effects 0.000 title claims description 4
- 230000009245 menopause Effects 0.000 title description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 208000035475 disorder Diseases 0.000 title description 2
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 claims description 33
- 229960004190 nomegestrol acetate Drugs 0.000 claims description 33
- 239000000583 progesterone congener Substances 0.000 claims description 33
- 229960005309 estradiol Drugs 0.000 claims description 28
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 26
- 229930182833 estradiol Natural products 0.000 claims description 26
- 239000000262 estrogen Substances 0.000 claims description 26
- 229940011871 estrogen Drugs 0.000 claims description 23
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 8
- 229960004911 nomegestrol Drugs 0.000 claims description 8
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 241000283073 Equus caballus Species 0.000 claims description 6
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 3
- -1 estradiol ester Chemical class 0.000 claims description 2
- 229960004766 estradiol valerate Drugs 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 30
- 238000011282 treatment Methods 0.000 description 20
- 210000004696 endometrium Anatomy 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000002357 endometrial effect Effects 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 238000009256 replacement therapy Methods 0.000 description 6
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 229960001616 chlormadinone acetate Drugs 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
- 206010051909 Endometrial atrophy Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 206010030247 Oestrogen deficiency Diseases 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 238000011285 therapeutic regimen Methods 0.000 description 4
- 150000000319 19-nortestosterones Chemical class 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 230000002927 anti-mitotic effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 201000006828 endometrial hyperplasia Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 206010061178 Genital haemorrhage Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 2
- 229960000606 medrogestone Drugs 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000000757 progestagenic effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 229920003071 Polyclar® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- RUJWZZRJSQGFCW-OGPYDZPMSA-N [(8s,9s,10r,13s,14s,17r)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RUJWZZRJSQGFCW-OGPYDZPMSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000002054 antogonadotrophic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 229960004913 dydrogesterone Drugs 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001207 micronized progesterone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000003145 progesterone derivatives Chemical class 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000979 synthetic dye Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/FR1999/002588 WO2001030356A1 (fr) | 1999-10-25 | 1999-10-25 | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| PCT/FR2000/002939 WO2001030357A1 (fr) | 1999-10-25 | 2000-10-24 | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20021949D0 NO20021949D0 (no) | 2002-04-25 |
| NO20021949L NO20021949L (no) | 2002-04-25 |
| NO327973B1 true NO327973B1 (no) | 2009-11-02 |
Family
ID=9542727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021949A NO327973B1 (no) | 1999-10-25 | 2002-04-25 | Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8168619B1 (sl) |
| EP (1) | EP1227814B1 (sl) |
| JP (1) | JP5036943B2 (sl) |
| KR (1) | KR100623788B1 (sl) |
| CN (1) | CN100553637C (sl) |
| AP (1) | AP1625A (sl) |
| AT (1) | ATE286400T1 (sl) |
| AU (1) | AU777704B2 (sl) |
| BR (1) | BRPI0014979B8 (sl) |
| CA (1) | CA2389025C (sl) |
| CZ (1) | CZ303248B6 (sl) |
| DE (1) | DE60017281T2 (sl) |
| DK (1) | DK1227814T3 (sl) |
| ES (1) | ES2235967T3 (sl) |
| HK (1) | HK1050472B (sl) |
| HU (1) | HU229382B1 (sl) |
| IL (2) | IL148953A0 (sl) |
| MX (1) | MXPA02004084A (sl) |
| NO (1) | NO327973B1 (sl) |
| NZ (1) | NZ518145A (sl) |
| OA (1) | OA12072A (sl) |
| PL (1) | PL199848B1 (sl) |
| PT (1) | PT1227814E (sl) |
| RU (1) | RU2261106C2 (sl) |
| SI (1) | SI1227814T1 (sl) |
| WO (2) | WO2001030356A1 (sl) |
| ZA (1) | ZA200203398B (sl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2754179B1 (fr) | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
| WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
| DE60217324T2 (de) | 2001-05-18 | 2007-04-26 | Pantarhei Bioscience B.V. | Pharmazeutische zusammensetzung für die hormonersatztherapie |
| ES2337129T3 (es) | 2001-05-23 | 2010-04-21 | Pantarhei Bioscience B.V. | Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal. |
| DK1390042T3 (da) | 2001-05-23 | 2008-03-31 | Pantarhei Bioscience Bv | System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse |
| DE60216630T2 (de) * | 2001-11-15 | 2007-09-20 | Pantarhei Bioscience B.V. | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie |
| CA2489271C (en) | 2002-06-11 | 2011-12-06 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| AU2003274941A1 (en) | 2002-06-11 | 2003-12-22 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| JP2005535624A (ja) * | 2002-06-25 | 2005-11-24 | ワイス | ホルモン関連症状の治療におけるシクロチオカルバメート誘導体の使用 |
| ES2299730T3 (es) | 2002-07-12 | 2008-06-01 | Pantarhei Bioscience B.V. | Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer. |
| SI1556058T1 (sl) | 2002-10-23 | 2008-02-29 | Pantarhei Bioscience Bv | Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka |
| DE602008001783D1 (de) | 2007-01-08 | 2010-08-26 | Pantarhei Bioscience Bv | Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens |
| CN107007611B (zh) * | 2017-06-02 | 2020-04-14 | 上海市计划生育科学研究所 | 醋酸诺美孕酮在制备治疗子宫内膜癌的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| JPS61243059A (ja) | 1985-04-19 | 1986-10-29 | Konishi Kagaku Kogyo Kk | 高純度４，４′−ジヒドロキシジフエニルスルホンの製造法 |
| DE3603644A1 (de) | 1986-02-06 | 1987-08-13 | Metabowerke Kg | Spannfutter zum einspannen von bohrern oder schlagbohrern |
| US5208225A (en) * | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
| ZA87332B (en) | 1986-02-27 | 1987-08-26 | Warner Lambert Co | Compositions containing fixed combinations |
| CA1332227C (en) | 1987-09-24 | 1994-10-04 | Robert F. Casper | Oral contraceptive formulation |
| US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
| US5276022A (en) | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
| US5256421A (en) | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
| FI101601B (fi) | 1987-09-24 | 1998-07-31 | Jencap Res Ltd | Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmist een valmistusmenetelmässä |
| HUT52382A (en) | 1988-03-14 | 1990-07-28 | Sandoz Ag | Process for producing pharmaceutical compositions comprising as active ingredient unsubstituted progestin in 19-position and estrogen in the given case |
| IE71203B1 (en) | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
| FR2695826B1 (fr) | 1992-09-21 | 1995-01-06 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
| US5554601A (en) | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US5552394A (en) | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
| US6613757B1 (en) | 1994-09-22 | 2003-09-02 | Board Of Regents, The University Of Texas System | Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy |
| SE9403389D0 (sv) | 1994-10-06 | 1994-10-06 | Astra Ab | Pharmaceutical composition containing derivattves of sex hormones |
| EP0843555B1 (en) | 1995-08-01 | 2003-08-27 | Isis Pharmaceuticals, Inc. | Liposomal oligonucleotide compositions |
| FR2737411B1 (fr) | 1995-08-01 | 1997-10-17 | Theramex | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques |
| US5888543A (en) | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
| WO2001030355A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation |
| FR2754179B1 (fr) | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
| DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| FR2776191B1 (fr) * | 1998-03-23 | 2002-05-31 | Theramex | Composition hormonale topique a effet systemique |
| WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
| PT1443966E (pt) * | 2001-11-15 | 2007-06-21 | Pantarhei Bioscience Bv | Método para a prevenção ou tratamento das doenças ginecológicas benignas |
| PE20081895A1 (es) | 2007-03-26 | 2009-01-26 | Theramex | Regimen anticonceptivo oral |
-
1999
- 1999-10-25 WO PCT/FR1999/002588 patent/WO2001030356A1/fr active Application Filing
- 1999-10-29 US US09/423,109 patent/US8168619B1/en not_active Expired - Fee Related
-
2000
- 2000-10-24 BR BRPI0014979A patent/BRPI0014979B8/pt not_active IP Right Cessation
- 2000-10-24 SI SI200030615T patent/SI1227814T1/sl unknown
- 2000-10-24 AT AT00971476T patent/ATE286400T1/de active
- 2000-10-24 CA CA002389025A patent/CA2389025C/fr not_active Expired - Lifetime
- 2000-10-24 RU RU2002113652/15A patent/RU2261106C2/ru not_active IP Right Cessation
- 2000-10-24 MX MXPA02004084A patent/MXPA02004084A/es active IP Right Grant
- 2000-10-24 CZ CZ20021427A patent/CZ303248B6/cs not_active IP Right Cessation
- 2000-10-24 HU HU0203721A patent/HU229382B1/hu not_active IP Right Cessation
- 2000-10-24 ES ES00971476T patent/ES2235967T3/es not_active Expired - Lifetime
- 2000-10-24 JP JP2001532775A patent/JP5036943B2/ja not_active Expired - Fee Related
- 2000-10-24 NZ NZ518145A patent/NZ518145A/en not_active IP Right Cessation
- 2000-10-24 OA OA1200200119A patent/OA12072A/fr unknown
- 2000-10-24 AP APAP/P/2002/002475A patent/AP1625A/en active
- 2000-10-24 IL IL14895300A patent/IL148953A0/xx active IP Right Grant
- 2000-10-24 WO PCT/FR2000/002939 patent/WO2001030357A1/fr active IP Right Grant
- 2000-10-24 DK DK00971476T patent/DK1227814T3/da active
- 2000-10-24 PL PL356847A patent/PL199848B1/pl unknown
- 2000-10-24 CN CNB008147841A patent/CN100553637C/zh not_active Expired - Fee Related
- 2000-10-24 EP EP00971476A patent/EP1227814B1/fr not_active Expired - Lifetime
- 2000-10-24 PT PT00971476T patent/PT1227814E/pt unknown
- 2000-10-24 AU AU10326/01A patent/AU777704B2/en not_active Ceased
- 2000-10-24 KR KR1020027005259A patent/KR100623788B1/ko active IP Right Grant
- 2000-10-24 DE DE60017281T patent/DE60017281T2/de not_active Expired - Lifetime
-
2002
- 2002-04-01 IL IL148953A patent/IL148953A/en unknown
- 2002-04-25 NO NO20021949A patent/NO327973B1/no not_active IP Right Cessation
- 2002-04-29 ZA ZA200203398A patent/ZA200203398B/en unknown
-
2003
- 2003-02-06 HK HK03100875.7A patent/HK1050472B/zh not_active IP Right Cessation
-
2012
- 2012-04-17 US US13/448,953 patent/US9084796B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9084796B2 (en) | Hormonal composition and its use | |
| KR101812160B1 (ko) | 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리 | |
| CA2079002C (en) | Ovulation-preventing agent for hormonal contraception | |
| US20100021529A1 (en) | Step-down estrogen regimen for women receiving estrogen therapy | |
| Erkkola et al. | Role of progestins in contraception | |
| CA2450359C (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| MXPA06013418A (es) | Composiciones y metodos para el tratamiento del trastorno disforico premenstrual. | |
| US6906049B1 (en) | Contraceptive medicine based on a progestational agent and an oestrogen and preparation method | |
| JP5484646B2 (ja) | 新規な避妊薬とその調製方法 | |
| KR20240047421A (ko) | 자궁내막증 치료 및 효과적인 피임 제공 방법 | |
| US20230135376A1 (en) | Multiphasic contraceptive and/or hormone replacement therapy | |
| KR20090119829A (ko) | 자궁내막증의 경감을 위한 제약 제제 | |
| EP1605924B1 (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
| KR20030043797A (ko) | 호르몬 조성물 | |
| 정숙김 et al. | Clinical use of oral contraceptives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |